Terug
Ook genoteerd als
RHHBY
OTC
Dagbereik
€ 378,00
€ 385,00
52-Weeksbereik
€ 288,90
€ 514,08
Volume
3
50D / 200D Gem.
€ 450,02
/
€ 384,75
Vorige Slotkoers
€ 397,80
Quick Summary
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 23,8 | 0,3 |
| P/B | 9,1 | 3,0 |
| ROE % | 39,3 | 3,7 |
| Net Margin % | 20,9 | 3,8 |
| Rev Growth 5Y % | -0,5 | 10,0 |
| D/E | 1,0 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 29,09
€ 27,55 – € 30,81
|
77,62B | 1 |
| FY2029 |
€ 25,94
€ 24,58 – € 27,48
|
73,23B | 1 |
| FY2028 |
€ 23,68
€ 22,43 – € 25,08
|
68,97B | 1 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2025-12-31 | N/A | € 8,60 | — |
| 2025-07-24 | € 13,18 | € 5,81 | -55,9% |
| 2025-01-30 | € 9,25 | € 2,77 | -70,1% |
| 2024-10-23 | € 10,42 | € 8,71 | -16,4% |
| 2024-04-26 | € 10,07 | € 6,34 | -37,0% |
| 2023-11-29 | € 11,62 | € 9,90 | -14,8% |
| 2023-02-02 | € 9,49 | € 5,26 | -44,6% |
| 2022-07-21 | € 11,53 | € 10,99 | -4,7% |
Dividend History
Yield
0,03%
Payout Ratio
N/A
Growth (3Y)
N/A
Growth (5Y)
N/A
No dividend history available.
Belangrijkste Punten
Revenue declined -0,50% annually over 5 years
Earnings grew 55,69% over the past year
ROE of 39,30% indicates high profitability
Net margin of 20,94% shows strong profitability
Generating 14,09B in free cash flow
PEG of 0,39 suggests growth is underpriced
Groei
Revenue Growth (5Y)
-0,50%
Revenue (1Y)-1,36%
Earnings (1Y)55,69%
FCF Growth (3Y)10,95%
Kwaliteit
Return on Equity
39,30%
ROIC17,98%
Net Margin20,94%
Op. Margin26,59%
Veiligheid
Debt / Equity
1,02
Current Ratio1,38
Interest Coverage12,13
Waardering
P/E Ratio
23,78
Forward P/EN/A
P/B Ratio9,06
EV/EBITDA20,49
Dividend Yield0,03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -1,36% | Revenue Growth (3Y) | 0,91% |
| Earnings Growth (1Y) | 55,69% | Earnings Growth (3Y) | 5,86% |
| Revenue Growth (5Y) | -0,50% | Earnings Growth (5Y) | -1,93% |
| Profitability | |||
| Revenue (TTM) | 61,55B | Net Income (TTM) | 12,89B |
| ROE | 39,30% | ROA | 12,79% |
| Gross Margin | 72,94% | Operating Margin | 26,59% |
| Net Margin | 20,94% | Free Cash Flow (TTM) | 14,09B |
| ROIC | 17,98% | FCF Growth (3Y) | 10,95% |
| Safety | |||
| Debt / Equity | 1,02 | Current Ratio | 1,38 |
| Interest Coverage | 12,13 | ||
| Dividends | |||
| Dividend Yield | 0,03% | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 23,78 | Forward P/E | N/A |
| P/B Ratio | 9,06 | P/S Ratio | 4,98 |
| PEG Ratio | 0,39 | Forward PEG | N/A |
| EV/EBITDA | 20,49 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 4,60% | ||
| Market Cap | 306,46B | Enterprise Value | 335,33B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 61,55B | 62,40B | 60,44B | 63,28B | 62,80B |
| Net Income | 12,89B | 8,28B | 11,50B | 12,42B | 13,93B |
| EPS (Diluted) | 16,05 | 10,32 | 14,30 | 15,37 | 16,20 |
| Gross Profit | 44,89B | 46,11B | 44,08B | 42,88B | 43,15B |
| Operating Income | 16,37B | 13,42B | 15,40B | 17,48B | 18,16B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 100,75B | 101,80B | 90,47B | 88,15B | 92,32B |
| Total Liabilities | 62,85B | 65,64B | 57,21B | 56,14B | 63,97B |
| Shareholders' Equity | 33,82B | 31,77B | 29,32B | 27,99B | 24,49B |
| Total Debt | 34,45B | 36,35B | 30,78B | 26,54B | 32,55B |
| Cash & Equivalents | 5,58B | 6,98B | 5,38B | 4,99B | 6,85B |
| Current Assets | 38,75B | 40,04B | 33,45B | 33,82B | 35,63B |
| Current Liabilities | 28,01B | 27,02B | 24,82B | 27,24B | 38,42B |